Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).
In the frontline setting, sunitinib has been one of the longest standing VEGF receptor tyrosine kinase inhibitors and is most often used to treat patients who have good or intermediate risk characterizations according to the Motzer criteria, George says.
Sunitinib is different than others in its class, George says, because it is given on an intermittent schedule – usually 4 weeks on and 2 weeks off. The dosing schedule of sunitinib allows for patients to recover from side effects but does not compromise the efficacy of the agent.
<<< View more from the 2013 European Cancer Congress